

# 1 Association between kidney measurements and 2 cognitive performance in patients with ischemic stroke

3 Running title: Kidney measures and Cognitive Function

4

5 Author name: Chunyan Zhang<sup>1</sup>, Guofang Xue<sup>1</sup>, Yanjuan Hou<sup>2</sup>, Pengfei Meng<sup>1</sup>,

6 Huizhong Gao<sup>1</sup>, Bo Bai<sup>1</sup>, Dongfang Li<sup>1</sup>

7

8 <sup>1</sup>Author affiliations: Department of Neurology, Second Hospital, Shanxi Medical

9 University, 382 Wuyi Road, Taiyuan, Shanxi, China;

10 <sup>2</sup>Author affiliations: Department of Nephrology, Second Hospital, Shanxi Medical

11 University, 382 Wuyi Road, Taiyuan, Shanxi, China.

12 \*Correspondence: Chunyan Zhang

13 Address: Second Hospital, Shanxi Medical University, 382 Wuyi Road, Taiyuan, Shanxi,

14 China;

15 Email: marzipanzcy@126.com

16

17

18

19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Abstract

**Background** Relationships between low estimated glomerular filtration rate (eGFR)

and albuminuria with poorer cognitive performance in patients with ischemic stroke

are less clear. Our aim was to retrospectively ascertain the associations between

these renal measures and cognitive performance in patients with ischemic stroke.

**Methods** Retrospective analysis was performed on 608 patients with acute

ischemic stroke. Urine albumin-creatinine ratio (UACR) and eGFR were obtained

from inpatient medical records. Global cognitive function via mini-mental state exam

(MMSE) and Montreal Cognitive Assessment (MoCA) was determined one month

after hospital discharge. The relationship between renal measures and cognitive

performance was assessed using univariate and multiple linear regression analyses.

**Results** Patients had an average age of  $66.6 \pm 4.1$  years, and 48% were females.

Average eGFR and UACR were  $88.4 \pm 12.9$  ml/min/1.73m<sup>2</sup> and  $83.6 \pm 314.2$  mg/g,

respectively. The number of patients with an eGFR of  $\geq 90$ , 60 to 89, and  $< 60$

ml/min/1.73 m<sup>2</sup> were (371, 61%), (207, 34%) and (30, 5%) respectively. The

proportions with a UACR  $< 30$  mg/g, 30-300mg/g and  $> 300$  mg/g were 56%, 39% and

5%. Multivariate adjusted models showed that eGFR was independently associated

with MMSE ( $\beta = -0.4$ ; 95% CI= -0.5,-0.4;  $p < 0.001$ ) and MoCA ( $\beta = -0.6$ ; 95% CI= -0.7,-

0.5;  $p < 0.001$ ). However, the correlations between UACR and MMSE and MoCA were

39 statistically non-significant.

40 **Conclusion** In patients with ischemic stroke, reduced eGFR but not albuminuria

41 was associated with lower cognitive performance. These results show that the eGFR

42 decline could be an effective indicator of cognitive impairment after a stroke.

43 Therefore, regular monitoring and early detection of mild renal dysfunction in

44 patients with acute ischemic stroke might be needed.

45 **Keywords:** cognitive performance, elderly, estimated glomerular filtration rate,

46 urine albumin-to-creatinine ratio, ischemic stroke

47

48

49

50

51

52

53

54

55

56

57

## 58 Introduction

59 Globally, cognitive impairment is a major health problem during old age. Due to  
60 better living conditions and healthcare, humans have extended lifespans, and this  
61 has led to a rapid increase in the prevalence of cognitive dysfunction disorders.(1)  
62 The identification of modifiable risk factors of cognitive decline or dementia is of  
63 vital importance in developing preventive strategies.(2) Chronic kidney disease (CKD)  
64 is a global health burden with a high economic cost to health systems. CKD is defined  
65 by indicators of renal dysfunction, such as estimated glomerular filtration rate  
66 (eGFR), and kidney damage, such as urine albumin-creatinine ratio (UACR).(3)  
67 Numerous cross-sectional or longitudinal studies have been performed to explore  
68 the relationship between kidney disease and cognitive dysfunction, but the available  
69 data are conflicting.(4-15)  
70 A recent study on the Northern Ireland Cohort for the Longitudinal Study of Ageing  
71 (NICOLA) revealed that decreased eGFR had a significant association with an  
72 increased risk of cognitive dysfunction in a cohort of older adults.(16) The Maastricht  
73 Study found albuminuria but not eGFR to be independently associated with cognitive  
74 impairment, specifically within the domain of information processing speed.  
75 However, both albuminuria and eGFR were more significantly associated with  
76 cognitive impairment in older individuals.(6) A prospective study in a Chinese

77 population aged 80 years and more found early-stage CKD to have a correlation with  
78 cognitive decline.(17) Palmer et al found that in the African-American population  
79 with type 2 diabetes (T2D), eGFR and albuminuria were associated with cognitive  
80 dysfunction, even in mild kidney disease.(18) Cognitive impairment was found to  
81 occur early in CKD.(19) However, Helmer et al did not find an increased risk of  
82 cognitive decline or dementia to be associated with low eGFR level. Rather, they  
83 found that a faster decline in eGFR and proteinuria was associated with incidence of  
84 cognitive impairment and dementia with a vascular component.(20)

85 The incidence of cognitive impairment after cerebrovascular accidents (CVA) in China  
86 is as high as 80.9%, including 48.91% for cognitive impairment without dementia and  
87 32.05% for cognitive impairment with dementia.(21) Patients with CVA are at a high  
88 risk of suffering cognitive dysfunction. CVA increased the relative risk of dementia by  
89 3.7-fold to 6.6-fold in older adults aged 61–74 years, and advanced the onset of  
90 dementia by nearly 10 years.(22) However, few studies have examined whether the  
91 association between low eGFR and albuminuria with poorer cognitive performance  
92 are limited to individuals with high-risk factors or patients with stroke. A longitudinal  
93 study found that CKD was independently related to incident dementia in patients  
94 with vascular risk factors and partly support a role for common vascular mechanisms  
95 as the underlying pathophysiology of AD dementia.(23) Recently, a study in patients

with TIA and stroke found CKD was not independently associated with either pre- or post-event dementia, suggesting that renal-specific mechanisms are unlikely to play an important role in aetiology.(24)

This study aimed to investigate whether low eGFR and albuminuria, measured by UACR, are independently and/or jointly associated with worse cognitive performance in patients with ischemic stroke.

## Materials and Methods

### Data source

Using a retrospective design, this study analyzed data from 608 patients aged 60 to 80 years with acute ischemic stroke within 72 hours of onset between January 2016 and December 2020 from inpatient medical records and a database of cognitive assessment results for outpatient visits one month after hospital discharge. Data was collected from September 1, 2019. During or after data collection, investigators had access to information that could identify individual patients. All patients were no history of a cognitive disorder before stroke and were able to complete the assessment, excluding patients who could not cooperate with the examination, such as aphasia or consciousness disorder. The study was conducted at the Department of Neurology, Second Hospital of Shanxi Medical University, Taiyuan, a tertiary hospital

in Shanxi, China. This study was approved by the Ethics Committee of the Second Hospital of Shanxi Medical University (NO. 2019YX214 ). The research was completed in accordance with Helsinki Declaration. Due to the retrospective nature of the study, informed consent of the patients was not required. The data included renal function parameters, such as serum creatinine and UACR, and cognitive function test findings, such as mini-mental status examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores.

## **Clinical and laboratory data**

Clinical data extracted from hospital records on admission, included systolic and diastolic blood pressure on admission, self-reported demographic characteristics (age, gender, height, weight, years of education, smoking and alcohol consumption status, and diabetes mellitus and hypertension history), laboratory results (total cholesterol, triglyceride, homocysteine, uric acid, fasting glucose, urea, creatinine, and UACR). Additionally, data on neural function assessment (National Institutes of Health Stroke Scale [NIHSS] score) were available. All patients were diagnosed as large artery atherosclerosis (LAA), cardioembolism (CE), small artery occlusion (SAO), stroke of other determined cause (SOC), and stroke of undetermined cause (SUC) according to TOAST classification.(25) Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared. eGFR was calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation, which is more accurate than the modification of diet in renal disease (MDRD) equation.(26)

137 
$$eGFR=141 \times \min(Scr/k, 1)^\alpha \times \max(Scr/k, 1)^{-1.209} \times 0.993^{\text{age}} \times 1.018 [\text{if female}]$$

138 Where serum creatinine (Scr) is expressed in mg/dL and age in years;  $\kappa$  is 0.7 for  
 139 females and 0.9 for males;  $\alpha$  is -0.329 for females and -0.411 for males; min  
 140 indicates the minimum of  $Scr/\kappa$  or 1, and max indicates the maximum of  $Scr/\kappa$  or 1.

## 141 **Cognitive impairment testing**

142 All the cognitive function tests were assessed by two neuropsychological assessors  
 143 trained in consistency using MMSE and MoCA one month after hospital discharge.  
 144 The MMSE and MoCA scores ranged from 0 to 30; higher scores indicated better  
 145 cognitive function. MMSE testing components included 30 point within four  
 146 dimensions: ten points for orientation, six for registration and memory, five for  
 147 attention and calculation, and nine for language and visuospatial abilities. MoCA  
 148 testing domains included visuospatial and executive function (5 points), naming (3  
 149 points), memory (5 points), attention (6 points), language/abstraction (5 points) and  
 150 orientation (6 points).

## 151 **Statistical analysis**

152 The study was based on analysis of data obtained from a retrospective design.  
 153 Patient characteristics were presented as means  $\pm$  standard deviations (SD) for  
 154 continuous variables, and categorical variables were reported as frequencies and  
 155 percentages. Differences between groups for continuous data were tested by one-



way analysis of variance (ANOVA). Differences between groups for proportions were tested with a Chi-square test. Data on UACR were not normally distributed; therefore, they were log-transformed before analysis. Standard definitions were used to categorize eGFR data into three groups, comprising  $\geq 90$  ml/min/1.73 m<sup>2</sup> as reference, 60–89 ml/min/1.73 m<sup>2</sup>, and  $< 60$  ml/min/1.73 m<sup>2</sup>. Thereafter, eGFR was analyzed as a continuous variable (per 5 mL/min/1.73 m<sup>2</sup> decreased). UACR values were categorized as  $< 30$  mg albumin/g creatinine (normal to mildly increased as reference), 30–300 mg/g (moderately increased), and  $> 300$  mg/g (severely increased). Multivariate linear regression was used to assess the association between eGFR or UACR and cognitive performance, with eGFR or UACR as the independent variable and MoCA and MMSE scores as the dependent variables. Two models, Models 1 and 2, were used for the regression analysis. Model 1 was crude, and multivariate-adjusted Model 2 was constructed to adjust for potential confounding variables associated with kidney function and/or cognitive function, including age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol consumption status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure (SBP), and either eGFR or UACR. Crude and adjusted  $\beta$  with 95% CIs are presented. Two-tailed  $P < 0.05$  was considered statistically significant. All analyses

were performed using Empower (R)([www.empowerstats.com](http://www.empowerstats.com), X&Y Solutions Inc., Boston, MA) and R (<http://www.R-project.org>).

## Results

### Population characteristics

Table 1 shows demographic and laboratory data on all 608 patients. Patients had a mean age of 66.6 years (SD: 4.1 years) and 48% of patients were females. Average eGFR and UACR were  $88.4 \pm 12.9$  ml/min/1.73 m<sup>2</sup> and  $83.6 \pm 314.2$  mg/g, respectively. Levels of eGFR were >90 ml/min/1.73m<sup>2</sup> (N=371, 61%), 60–89 ml/min/1.73m<sup>2</sup> (N=207, 34%), and <60 ml/min/1.73m<sup>2</sup> (N=30, 5%). The number of patients with UACR<30 mg/g was 338 (56%). Moderately increased UACR, defined as a UACR 30–300mg/g, was present in 240(39%) of patients, and severely increased UACR, defined as a UACR >300 mg/g, was present in 30(5%) of patients. Patients with lower eGFR categories were more likely to be older and former or current alcohol consumers and smokers. In addition, they were more likely to have diabetes mellitus, and hypertensive disease, and high systolic blood pressure (SBP) and diastolic blood pressure (DBP) on admission. Their homocysteine, blood glucose, uric acid, and total cholesterol levels were more likely to be higher, as well as a higher BMI. The eGFR levels were lower in patients with albuminuria than in normal

patients. As compared with patients with UACR <30 mg/g, patients with UACR ≥30 mg/g were more likely to be living with obesity, diabetes mellitus, and hypertensive disease. Additionally, they were more likely to have higher SBP and DBP, blood glucose, uric acid, and homocysteine levels. Patients had lower cognitive scores in the lower eGFR and higher UACR categories (Table 1).

## **Independent and combined associations between eGFR and UACR levels and cognitive performance**

Table 2 contains the results of unadjusted and fully adjusted (age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol consumption status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, SBP, and eGFR or UACR) models for continuous and categorical relationships between measures of renal disease and cognitive tests. The correlation between UACR and MMSE and MoCA scores in crude and multivariate adjustment were statistically non-significant. In the crude and adjusted analyses, no independent associations were observed between UACR, as a category, and cognitive performance. Similarly, no independent associations were observed when UACR was analyzed as a continuous variable in Models 1 and 2 (Table 2). The association between eGFR and the tests of cognitive performance was evaluated with crude and multivariable linear regression analyses. eGFR was analyzed as a

213 categorical ( $\geq 90$ , 60-90, and  $< 60$  ml/min/1.73 m<sup>2</sup>) and a continuous (per 5  
214 ml/min/1.73 m<sup>2</sup> decrease) variable. In the multivariable adjustment model, for  
215 patients with eGFR 60–90 ml/min/1.73 m<sup>2</sup> compared to patients with eGFR  $\geq 90$   
216 ml/min/1.73 m<sup>2</sup>, an association existed between eGFR and MMSE ( $\beta$ , -0.7; 95%CI, -  
217 1.0 to -0.3) and MoCA ( $\beta$ , -1.4; 95%CI, -1.7 to -1.0). The association between eGFR  
218  $< 60$  ml/min/1.73 m<sup>2</sup> and cognitive performance was stronger. In the multivariable  
219 adjustment model, MMSE and MoCA were ( $\beta$ , -4.2; 95%CI -5.0, -3.4) and ( $\beta$ , -5.2;  
220 95%CI -6.1, -4.4), respectively. When examined as a continuous variable (per 5  
221 ml/min/1.73 m<sup>2</sup> decrease) in crude and fully adjusted models, eGFR decrements  
222 were positively associated with lower MMSE and MoCA scores ( $p < 0.001$ ) (Table 2). In  
223 all cases, lower levels of eGFR were associated with poorer cognitive performance.  
224 To assess generalizability, a fully adjusted regression model was created for  
225 analyzing the subgroups of sex, stroke subtypes, age, SBP, NIHSS, and blood glucose  
226 levels. The results were similar in the subgroup analyses. No significant interactions  
227 were found among any of the stratified variables (male versus female, large artery  
228 versus small vessel occlusion, age, SBP, NIHSS, and blood glucose dichotomized  
229 group: higher versus lower) with eGFR or UACR for cognitive testing. (Tables 3 and 4)  
230 When combined categories of eGFR ( $< 90$  and  $\geq 90$  ml/min/1.73 m<sup>2</sup>) and albuminuria  
231 ( $< 30$  and  $\geq 30$  mg/g) were analyzed, the MMSE and MoCA scores were the least in

232 those patients with UACR  $\geq 30$  mg/g and eGFR  $< 90$  ml/min/1.73 m<sup>2</sup>, compared to  
 233 those without albuminuria and eGFR level of  $\geq 90$  ml/min/1.73 m<sup>2</sup> in the crude and  
 234 fully adjusted model (Table 5).

235

## 236 Discussion

237 This study found that in old adults with ischemic stroke in China, reduced eGFR, but  
 238 not albuminuria measured by UACR, has an independent association with poorer  
 239 cognitive performance. This study supports findings from prior studies reporting a  
 240 link between kidney function and cognitive impairment.

## 241 eGFR and cognitive performance

242 Our results showed that, in the absence or presence of albuminuria, an eGFR  $< 90$   
 243 ml/min/1.73 m<sup>2</sup> had an association with worse cognitive performance. However, the  
 244 presence of albuminuria amplified the relationship. These findings corroborate the  
 245 findings of prior studies on the association between renal measures and poorer  
 246 cognitive performance. According to previous reports, this association exists during  
 247 the early stages of renal dysfunction.(17, 18) The association between renal function  
 248 and cognitive performance has been paid much attention in recent decades. Wang  
 249 et al found that both CKD and eGFR were associated with cognitive dysfunction  
 250 among older patients with hypertension in China.(27) A prospective study

251 demonstrated that kidney dysfunction is associated with a cognitive decline in a  
 252 community-based population, and this association is independent of  
 253 albuminuria.(28) Another longitudinal study suggested that a low eGFR was  
 254 associated with increased risk of dementia. In addition, a faster decrease in eGFR  
 255 and proteinuria was associated with incidence of cognitive impairment and  
 256 dementia; this association may be mediated by vascular mechanisms.(20)  
 257 Additionally, a large population study found that each 10 ml/min/1.73 m<sup>2</sup> decrease  
 258 in eGFR<60 ml/min/1.73 m<sup>2</sup> was independently associated with an increased  
 259 prevalence of cognitive impairment.(29) The OSACA2 study found that CKD was  
 260 independently related to incident dementia in patients with vascular risk factors.(23)  
 261 However, one cohort study from the Oxford Vascular Study (OXVASC) did not find  
 262 CKD was associated with either pre- or postevent dementia in patients with TIA and  
 263 stroke.(24) The inconsistent results may be attributable to different study  
 264 populations and severity of lesion. OXVASC has focused on the relationship between  
 265 CKD and dementia in the patients with TIA and stroke. Participants in SPRINT were in  
 266 older community-dwelling adults with cardiovascular disease. OSACA2 was in high-  
 267 risk patients for the primary and secondary prevention of cardiovascular disease.  
 268 Another potential reason is different methods of assessment. Many previous studies  
 269 have used different assessment tools to evaluate cognitive function.

270 Although the precise pathophysiologic mechanisms that underlie the association  
 271 between low eGFR and poorer cognitive performance are not known and need  
 272 further studies for clarity, several factors may help explain the association between  
 273 low eGFR and cognitive dysfunction. Patients with renal dysfunction have a higher  
 274 prevalence of cerebrovascular disease (CVD) than the general population. Renal  
 275 dysfunction may contribute to vascular cognitive impairment through traditional  
 276 CVD risk factors, including hypertension, diabetes mellitus, dyslipidemia, smoking,  
 277 and other non-traditional vascular risk factors comprising hyperhomocysteinemia,  
 278 hyperuricemia, anemia, inflammation, and oxidative stress. Moreover, CKD  
 279 characterized by the accumulation of uremic toxins, excessive RAS activation, renal  
 280 anemia, and renal osteopathy, caused by renal dysfunction are possible mechanisms  
 281 of renal disease involvement in the progression of dementia.(30, 31) Conceptually,  
 282 low eGFR may lead to the accumulation of neurotoxins or may represent a  
 283 prolonged exposure to CVD or its risk factors.(6) Vascular dementia is often linked to  
 284 hypertension, which is a common finding in CKD. Hypertension has often been  
 285 associated with small lacunar infarcts and leukoariosis, cerebral autoregulation  
 286 dysfunction, and chronic hypoperfusion. Although cerebral blood flow may be  
 287 adequate in CKD, the blood–brain barrier or the glymphatic system might be  
 288 dysfunctional. In this study, more than 50% of the patients had hypertension. Uremic

289 toxins in circulation, which enter the central nervous system (CNS) as a result of  
290 blood-brain barrier damage during kidney dysfunction, might impair CNS structure  
291 and function.(32)

## 292 **Albuminuria and cognitive performance**

293 According to recent systematic review and meta-analysis studies, albuminuria has a  
294 significant association with cognitive impairment and dementia.(4, 33, 34) To the  
295 best of our knowledge, albuminuria is a significant risk factor for the development of  
296 dementia in community-based Japanese older adults. Moreover, low eGFR and  
297 albuminuria are mutually associated with a greater risk of vascular dementia.(35) A  
298 prospective cohort study demonstrated that persistent or progressive albuminuria is  
299 associated with cognitive decline in adults with diabetes and normal eGFR.(36) Wei  
300 et al found that urine albumin is significantly associated with cognitive dysfunction,  
301 and can be potentially used as an early marker for CKD.(37)

302 The mechanism underlying the association between albuminuria and poorer  
303 cognition is not completely understood and is likely multifactorial. Both cerebral and  
304 renal circulations have high flow and low impedance. The association between  
305 albuminuria and cognitive impairment probably reflects common microvascular  
306 pathogenesis in the kidneys and brain. Several reasons may explain the  
307 inconsistencies between our findings and those of previous reports. First, the



308 conflicting results may be attributable to use of different study populations in  
309 studying the severity of albuminuria. Patients with cognitive dysfunction may reflect  
310 in another chronic microvascular disease. This may explain why dementia and poorer  
311 cognitive performance are more common in individuals with diabetes who have a  
312 high prevalence of albuminuria.(36, 38) However, since fewer patients with diabetes  
313 participated in this study (8%), these findings should be interpreted with caution.  
314 The study might be underpowered to detect the association between UACR and  
315 poorer cognitive performance. Second, this study only measured UACR at a single  
316 time point. UACR is affected by exercise and the time of day the sample is taken,(39)  
317 which is why repeated measurements would be preferred. The true association  
318 between albuminuria and cognitive performance is likely to be diluted. An  
319 alternative explanation for the disparate results of the association between low  
320 eGFR and albuminuria and poorer cognitive performance could be that albuminuria  
321 is a marker for a different condition other than kidney disease.(40)  
322 This study had several strengths. First, the primary independent and dependent  
323 variables were quantified using clinically relevant measures (eGFR and UACR for two  
324 independent markers of renal function and damage and MoCA and MMSE for  
325 cognitive performance), thus providing clinical relevance to the analyses. In addition,  
326 the use of both eGFR and UACR as correlators enabled us to test their independent

327 and joint effects on cognitive performance. Second, the study controlled for several  
328 potential confounders, including demographic and clinical parameters, while  
329 assessing the association.

330 Several limitations were noted. First, our study population contained a small number  
331 of patients with CKD (eGFR <60 ml/min/1.73 m<sup>2</sup>), which limited our ability to detect  
332 a relationship between eGFR <60 ml/min/1.73 m<sup>2</sup> and cognitive performance.

333 Second, these parameters were based on a one-time evaluation and do not provide  
334 information on the duration or severity of risk factors over time. Third, we did not  
335 analyze impairment in specific cognitive domains; instead, overall cognitive scores  
336 were used in the analysis. Finally, the cognitive assessment was performed one  
337 month after hospital discharge, and the incidence of post-stroke cognitive  
338 impairment is highest three months after stroke.<sup>(41)</sup> Further long-term follow-up is  
339 still needed.

340 Our findings support the hypothesis that renal dysfunction and albuminuria may  
341 operate through different pathophysiologic mechanisms. They further suggest that  
342 the pathways mediating the association between low eGFR and albuminuria and  
343 poorer cognitive performance may be partially distinct. The findings have clinical  
344 implications. Our results suggest that the measurement of eGFR is a good biomarker  
345 for cognitive impairment in patients with acute ischemic stroke. Low eGFR may

reflect a partially distinct pathophysiologic process of cognitive dysfunction.

Targeting the pathogenesis of low eGFR or treating modifiable risk factors may have clinical implications in preventing cognitive impairment or delaying disease progression. Further studies are needed to confirm whether the setting of kidney dysfunction is a possible new determinant for cognitive impairment in patients with stroke.

## Conclusion

Our findings suggest that in patients with ischemic stroke, reduced eGFR but not albuminuria was associated with cognitive impairment, measured by MMSE or MoCA. The eGFR decline could be an effective indicator of cognitive impairment after a stroke. These results suggest that the early stages of renal dysfunction could be an effective target to prevent cognitive impairment in patients with stroke. It emphasizes the need and possibility for early detection and early cognitive impairment prevention after stroke.

## Acknowledgments

None.

## References

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2013 Jan;9(1):63-75.e2. PubMed PMID: 23305823. Epub 2013/01/12. eng.
2. Plassman BL, Williams JW, Jr., Burke JR, Holsinger T, Benjamin S. Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. *Annals of internal medicine*. 2010 Aug 3;153(3):182-93. PubMed PMID: 20547887. Epub 2010/06/16. eng.
3. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. *PloS one*. 2016;11(7):e0158765. PubMed PMID: 27383068. Pubmed Central PMCID: Pmc4934905. Epub 2016/07/08. eng.
4. Deckers K, Camerino I, van Boxtel MP, Verhey FR, Irving K, Brayne C, et al. Dementia risk in renal dysfunction: A systematic review and meta-analysis of prospective studies. *Neurology*. 2017 Jan 10;88(2):198-208. PubMed PMID: 27974647. Pubmed Central PMCID: Pmc5224710. Epub 2016/12/16. eng.
5. Weiner DE, Gaussoin SA, Nord J, Auchus AP, Chelune GJ, Chonchol M, et al. Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT). *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2017 Sep;70(3):357-67. PubMed PMID: 28606731. Pubmed Central PMCID: Pmc5572661. Epub 2017/06/14. eng.
6. Martens RJ, Kooman JP, Stehouwer CD, Dagnelie PC, van der Kallen CJ, Koster A, et al. Estimated GFR, Albuminuria, and Cognitive Performance: The Maastricht Study. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2017 Feb;69(2):179-91. PubMed PMID: 27291486. Epub 2016/06/14. eng.
7. Ekblad LL, Toppala S, Johansson JK, Koskinen S, Sundvall J, Rinne JO, et al. Albuminuria and Microalbuminuria as Predictors of Cognitive Performance in a General Population: An 11-Year Follow-Up Study. *Journal of Alzheimer's disease : JAD*. 2018;62(2):635-48. PubMed PMID: 29480195. Epub 2018/02/27. eng.
8. Kong JY, Kim JS, Kang MH, Hwang HS, Won CW, Jeong KH. Renal dysfunction is associated with decline of cognitive function in community-dwelling older adults: Korean frailty and aging cohort study. 2020 Nov 10;20(1):462. PubMed PMID: 33172388.
9. Etgen T, Chonchol M, Förstl H, Sander D. Chronic kidney disease and cognitive impairment: a systematic review and meta-analysis. *American journal of nephrology*. 2012;35(5):474-82. PubMed PMID: 22555151. Epub 2012/05/05. eng.
10. Kurella Tamura M, Yaffe K, Hsu CY, Yang J, Sozio S, Fischer M, et al. Cognitive Impairment and Progression of CKD. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2016 Jul;68(1):77-83. PubMed PMID: 26972681. Pubmed Central PMCID: Pmc4921255. Epub 2016/03/15. eng.
11. Joosten H, Izaks GJ, Slaets JP, de Jong PE, Visser ST, Bilo HJ, et al. Association of cognitive function with albuminuria and eGFR in the general population. *Clinical journal of the American Society of Nephrology : CJASN*. 2011 Jun;6(6):1400-9. PubMed PMID: 21566108. Pubmed Central PMCID: Pmc3109938. Epub 2011/05/14. eng.
12. Barzilay JI, Younes N, Pop-Busui R, Florez H, Seaquist E, Falck-Ytter C, et al. The cross-sectional association of renal dysfunction with tests of cognition in middle-aged adults with early type 2 diabetes: The GRADE Study. *Journal of diabetes and its*

415 complications. 2021 Mar;35(3):107805. PubMed PMID: 33288412. Pubmed Central  
416 PMCID: Pmc7870547. Epub 2020/12/09. eng.

417 13. Feng L, Yap KB, Yeoh LY, Ng TP. Kidney function and cognitive and functional  
418 decline in elderly adults: findings from the Singapore longitudinal aging study.  
419 Journal of the American Geriatrics Society. 2012 Jul;60(7):1208-14. PubMed PMID:  
420 22702744. Epub 2012/06/19. eng.

421 14. Kono S, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, et al.  
422 Impact of cystatin C and microalbuminuria on cognitive impairment in the population  
423 of community-dwelling Japanese. Atherosclerosis. 2017 Oct;265:71-7. PubMed PMID:  
424 28865325. Epub 2017/09/03. eng.

425 15. Lee S, Shimada H, Park H, Makizako H, Lee S, Doi T, et al. The association  
426 between kidney function and cognitive decline in community-dwelling, elderly  
427 Japanese people. Journal of the American Medical Directors Association. 2015  
428 Apr;16(4):349.e1-5. PubMed PMID: 25669668. Epub 2015/02/12. eng.

429 16. Paterson EN, Maxwell AP, Kee F, Cruise S, Young IS, McGuinness B, et al.  
430 Association of renal impairment with cognitive dysfunction in the Northern Ireland  
431 Cohort for the Longitudinal Study of Ageing (NICOLA). 2021 Jul 23;36(8):1492-9.  
432 PubMed PMID: 34038557.

433 17. Bai K, Pan Y, Lu F, Zhao Y, Wang J, Zhang L. Kidney function and cognitive  
434 decline in an oldest-old Chinese population. Clinical interventions in aging.  
435 2017;12:1049-54. PubMed PMID: 28740370. Pubmed Central PMCID: Pmc5505158.  
436 Epub 2017/07/26. eng.

437 18. Palmer ND, Sink KM, Smith SC, Xu J, Bowden DW, Hugenschmidt CE, et al.  
438 Kidney disease and cognitive function: African American-diabetes heart study MIND.  
439 American journal of nephrology. 2014;40(3):200-7. PubMed PMID: 25323981.  
440 Pubmed Central PMCID: Pmc4216628. Epub 2014/10/18. eng.

441 19. Berger I, Wu S, Masson P, Kelly PJ, Duthie FA, Whiteley W, et al. Cognition in  
442 chronic kidney disease: a systematic review and meta-analysis. BMC medicine. 2016  
443 Dec 14;14(1):206. PubMed PMID: 27964726. Pubmed Central PMCID: Pmc5155375.  
444 Epub 2016/12/15. eng.

445 20. Helmer C, Stengel B, Metzger M, Froissart M, Massy ZA, Tzourio C, et al.  
446 Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study.  
447 Neurology. 2011 Dec 6;77(23):2043-51. PubMed PMID: 22116945. Epub 2011/11/26.  
448 eng.

449 21. Qu Y, Zhuo L, Li N, Hu Y, Chen W, Zhou Y, et al. Prevalence of post-stroke  
450 cognitive impairment in china: a community-based, cross-sectional study. PloS one.  
451 2015;10(4):e0122864. PubMed PMID: 25874998. Pubmed Central PMCID:  
452 Pmc4395303. Epub 2015/04/16. eng.

453 22. De Ronchi D, Palmer K, Pioggiosi P, Atti AR, Berardi D, Ferrari B, et al. The  
454 combined effect of age, education, and stroke on dementia and cognitive impairment  
455 no dementia in the elderly. Dementia and geriatric cognitive disorders.  
456 2007;24(4):266-73. PubMed PMID: 17700023. Epub 2007/08/19. eng.

457 23. Miwa K, Tanaka M, Okazaki S, Furukado S, Yagita Y, Sakaguchi M, et al.  
458 Chronic kidney disease is associated with dementia independent of cerebral small-  
459 vessel disease. Neurology. 2014 Mar 25;82(12):1051-7. PubMed PMID: 24553427.  
460 Epub 2014/02/21. eng.

461 24. Kelly DM, Pendlebury ST. Associations of Chronic Kidney Disease With  
462 Dementia Before and After TIA and Stroke: Population-Based Cohort Study. 2022  
463 Feb 15;98(7):e711-e20. PubMed PMID: 34996878.

464 25. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al.  
465 Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter

466 clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993  
467 Jan;24(1):35-41. PubMed PMID: 7678184. Epub 1993/01/01. eng.

468 26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et  
469 al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May  
470 5;150(9):604-12. PubMed PMID: 19414839. Pubmed Central PMCID: Pmc2763564.  
471 Epub 2009/05/06. eng.

472 27. Wang H, Liu T, Cai YY, Jiang H, Liu HX, Lin C. Kidney Function and Cognitive  
473 Impairment in People Aged 80 Years and Over with Untreated Hypertension: A  
474 Cross-Sectional Survey. Kidney & blood pressure research. 2016;41(1):70-7. PubMed  
475 PMID: 26872346. Epub 2016/02/13. eng.

476 28. Wang F, Zhang L, Liu L, Wang H. Level of kidney function correlates with  
477 cognitive decline. American journal of nephrology. 2010;32(2):117-21. PubMed PMID:  
478 20714128. Epub 2010/08/18. eng.

479 29. Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, et al.  
480 Kidney function and cognitive impairment in US adults: the Reasons for Geographic  
481 and Racial Differences in Stroke (REGARDS) Study. American journal of kidney  
482 diseases : the official journal of the National Kidney Foundation. 2008  
483 Aug;52(2):227-34. PubMed PMID: 18585836. Pubmed Central PMCID: Pmc2593146.  
484 Epub 2008/07/01. eng.

485 30. Kurella Tamura M, Xie D, Yaffe K, Cohen DL, Teal V, Kasner SE, et al.  
486 Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic  
487 Renal Insufficiency Cohort (CRIC) study. Clinical journal of the American Society of  
488 Nephrology : CJASN. 2011 Feb;6(2):248-56. PubMed PMID: 20930087. Pubmed  
489 Central PMCID: Pmc3052213. Epub 2010/10/12. eng.

490 31. Zhang J, Tang L, Hu J, Wang Y, Xu Y. Uric acid is associated with cognitive  
491 impairment in the elderly patients receiving maintenance hemodialysis-A two-center  
492 study. 2020 Mar;10(3):e01542. PubMed PMID: 31985179.

493 32. Viggiano D, Wagner CA, Martino G. Mechanisms of cognitive dysfunction in  
494 CKD. 2020 Aug;16(8):452-69. PubMed PMID: 32235904.

495 33. Georgakis MK, Dimitriou NG, Karalexi MA, Mihos C, Nasothimiou EG,  
496 Tousoulis D, et al. Albuminuria in Association with Cognitive Function and Dementia:  
497 A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society.  
498 2017 Jun;65(6):1190-8. PubMed PMID: 28152169. Epub 2017/02/06. eng.

499 34. Li H, Zhao S, Wang R, Gao B. The association between cognitive  
500 impairment/dementia and albuminuria: a systematic review and meta-analysis.  
501 Clinical and experimental nephrology. 2021 Aug 28. PubMed PMID: 34468878. Epub  
502 2021/09/02. eng.

503 35. Takae K, Hata J, Ohara T, Yoshida D, Shibata M, Mukai N, et al. Albuminuria  
504 Increases the Risks for Both Alzheimer Disease and Vascular Dementia in  
505 Community-Dwelling Japanese Elderly: The Hisayama Study. Journal of the American  
506 Heart Association. 2018 Jan 20;7(2). PubMed PMID: 29353232. Pubmed Central  
507 PMCID: Pmc5850144. Epub 2018/01/22. eng.

508 36. Barzilay JI, Lovato JF, Murray AM, Williamson J, Ismail-Beigi F, Karl D, et al.  
509 Albuminuria and cognitive decline in people with diabetes and normal renal function.  
510 Clinical journal of the American Society of Nephrology : CJASN. 2013  
511 Nov;8(11):1907-14. PubMed PMID: 23990163. Pubmed Central PMCID: Pmc3817915.  
512 Epub 2013/08/31. eng.

513 37. Wei Y, Wei YK, Zhu J. Early markers of kidney dysfunction and cognitive  
514 impairment among older adults. Journal of the neurological sciences. 2017 Apr  
515 15;375:209-14. PubMed PMID: 28320132. Epub 2017/03/23. eng.

516 38. Barzilay JI, Gao P, O'Donnell M, Mann JF, Anderson C, Fagard R, et al.  
517 Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies.

518 Archives of internal medicine. 2011 Jan 24;171(2):142-50. PubMed PMID: 21263104.  
 519 Epub 2011/01/26. eng.  
 520 39. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, et al.  
 521 Current issues in measurement and reporting of urinary albumin excretion. Clinical  
 522 chemistry. 2009 Jan;55(1):24-38. PubMed PMID: 19028824. Epub 2008/11/26. eng.  
 523 40. Fried L. Albuminuria and cognitive impairment. Clinical journal of the  
 524 American Society of Nephrology : CJASN. 2012 Mar;7(3):376-8. PubMed PMID:  
 525 22282483. Epub 2012/01/28. eng.  
 526 41. Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology,  
 527 mechanisms and management. Annals of translational medicine. 2014 Aug;2(8):80.  
 528 PubMed PMID: 25333055. Pubmed Central PMCID: Pmc4200648. Epub 2014/10/22.  
 529 eng.

530

531

532



Table 1 Demographic and clinical characteristics of patients stratified by eGFR and UACR

	Overall n=608	Estimated glomerular filtration(ml/min/1.73 m <sup>2</sup> )			<i>P</i> value	Urinary ACR (mg/g)			<i>P</i> value
		≥90	60-89	<60		<30	30-300	>300	
		n=371	n=207	n=30		n=338	n=240	n=30	
Age, y	66.6 ± 4.1	65.5 ± 3.5	68.0 ± 4.5	69.8 ± 4.5	<0.001	66.4 ± 4.2	66.8 ± 4.1	66.3 ± 3.7	0.45
Male, n(%)	316 (52.0)	192 (51.8)	105 (50.7)	19 (63.3)	0.43	186 (55.0)	115 (47.9)	15 (50.0)	0.235
BMI, <sup>a</sup> kg/m <sup>2</sup>	25.0 ± 3.6	24.8 ± 3.4	24.9 ± 3.8	26.6 ± 4.0	0.033	24.6 ± 3.4	25.3 ± 3.7	25.9 ± 3.8	0.019
Education (> 6 years),n (%)	200 (32.9)	130 (35.0)	58 (28.0)	12 (40.0)	0.158	113 (33.4)	77 (32.1)	10 (33.3)	0.943
Systolic blood pressure on admission, mmHg	171.9 ± 20.2	170.0 ± 19.8	174.2 ± 20.7	178.9 ± 19.4	0.008	170.3 ± 18.4	173.8 ± 22.1	174.8 ± 23.3	0.079
Diastolic blood pressure on admission, mmHg	92.9 ± 12.2	92.1 ± 12.1	93.9 ± 12.4	96.5 ± 12.7	0.057	91.5 ± 11.7	94.6 ± 12.7	95.5 ± 12.8	0.006
Smoking, n (%)					0.112				0.057
Never	355 (58.5)	229 (61.7)	114 (55.3)	12 (40.0)		182 (54.0)	153 (63.7)	20 (66.7)	
Former	64 (10.5)	33 (8.9)	26 (12.6)	5 (16.7)		34 (10.1)	26 (10.8)	4 (13.3)	
Current	188 (31.0)	109 (29.4)	66 (32.0)	13 (43.3)		121 (35.9)	61 (25.4)	6 (20.0)	
Alcohol drinking, n (%)					0.474				0.18
Never	389 (64.0)	245 (66.0)	128 (61.8)	16 (53.3)		205 (60.7)	163 (67.9)	21 (70.0)	
Former	52 (8.6)	27 (7.3)	21 (10.1)	4 (13.3)		33 (9.8)	15 (6.2)	4 (13.3)	
Current	167 (27.5)	99 (26.7)	58 (28.0)	10 (33.3)		100 (29.6)	62 (25.8)	5 (16.7)	



Diabetes mellitus, <sup>b</sup> n (%)	50 (8.2)	34 (9.2)	13 (6.3)	3 (10.0)	0.45	21 (6.2)	23 (9.6)	6 (20.0)	0.019
Hypertension, n (%)	361 (59.4)	215 (58.0)	127 (61.4)	19 (63.3)	0.656	189 (55.9)	154 (64.2)	18 (60.0)	0.138
Stroke subtypes					0.149				0.911
Large artery	281 (46.2)	183 (49.3)	80 (38.6)	18 (60.0)		156 (46.2)	110 (45.8)	15 (50.0)	
Small vessel occlusion	309 (50.8)	176 (47.4)	121 (58.5)	12 (40.0)		171 (50.6)	124 (51.7)	14 (46.7)	
Cardioembolism	13 (2.1)	9 (2.4)	4 (1.9)	0 (0.0)		8 (2.4)	4 (1.7)	1 (3.3)	
Other determined etiology	3 (0.5)	1 (0.3)	2 (1.0)	0 (0.0)		1 (0.3)	2 (0.8)	0 (0.0)	
Undetermined etiology	2 (0.3)	2 (0.5)	0 (0.0)	0 (0.0)		2 (0.6)	0 (0.0)	0 (0.0)	
Laboratory results									
Total cholesterol, mmol/L	5.7 ± 1.2	5.6 ± 1.1	5.8 ± 1.3	5.8 ± 1.3	0.055	5.7 ± 1.2	5.7 ± 1.2	6.0 ± 1.1	0.423
Triglyceride, mmol/L	1.6 ± 0.9	1.7 ± 1.1	1.5 ± 0.7	1.6 ± 0.7	0.036	1.5 ± 0.8	1.8 ± 1.1	1.6 ± 0.5	0.016
Homocysteine, umol/L	16.1 ± 9.4	14.7 ± 7.9	17.0 ± 8.6	27.9 ± 18.7	<0.001	15.5 ± 7.1	17.0 ± 11.7	17.1 ± 10.2	0.124
Uric Acid, mmol/L	298.6 ± 75.4	284.5 ± 68.9	312.3 ± 75.2	377.7 ± 89.6	<0.001	299.0 ± 71.8	296.2 ± 79.5	313.0 ± 81.9	0.511
Fasting glucose, mmol/L	6.1 ± 1.8	6.2 ± 2.0	6.1 ± 1.6	6.3 ± 1.4	0.698	6.0 ± 1.7	6.2 ± 1.9	6.7 ± 2.5	0.082
Estimated glomerular filtration rate, mL/min/1.73m <sup>2</sup>	88.4 ± 12.9	96.0 ± 5.3	79.8 ± 8.5	53.2 ± 8.2	<0.001	89.0 ± 11.9	88.3 ± 13.0	81.8 ± 19.8	0.013
Log10 Urinary ACR	1.5 ± 0.5	1.5 ± 0.5	1.5 ± 0.4	1.7 ± 0.7	0.246	1.2 ± 0.2	1.8 ± 0.3	2.8 ± 0.3	<0.001
Neural function assessment, mean (SD)									
MMSE score, mean ± SD (range 0–30)	21.4 ± 2.1	22.0 ± 1.9	21.1 ± 1.6	17.5 ± 2.8	<0.001	21.5 ± 2.0	21.4 ± 2.1	20.8 ± 2.9	0.18

MoCA score, mean $\pm$ SD (range 0–30)	17.9 $\pm$ 2.3	18.7 $\pm$ 2.0	17.2 $\pm$ 1.9	13.4 $\pm$ 2.6	<0.001	18.0 $\pm$ 2.3	17.9 $\pm$ 2.3	17.2 $\pm$ 2.8	0.18
NIHSS score, mean $\pm$ SD (range 0–24)	5.0 $\pm$ 2.2	5.1 $\pm$ 2.3	4.8 $\pm$ 2.1	5.6 $\pm$ 1.8	0.091	5.1 $\pm$ 2.2	4.8 $\pm$ 2.1	5.3 $\pm$ 2.8	0.302

Abbreviations: BMI, body mass index. UACR: urine albumin-creatinine ratio

Values are presented as mean  $\pm$  SD for continuous variables and n (%) for categorical variables.

<sup>a</sup>BMI was calculated as weight in kilograms divided by height in meters squared.

<sup>b</sup>Diabetes mellitus was defined as self-reported physician diagnosed diabetes.

<sup>c</sup>Hypertension was defined as self-reported physician diagnosed hypertension.

Table 2 Linear regression analysis of the association between levels of eGFR and albuminuria measured by UACR and cognitive performance

Variables	No. of patients (%)	MMSE				MoCA			
		Crude		adjusted*		Crude		adjusted*	
		$\beta$ (95%CI)	P	$\beta$ (95%CI)	P	$\beta$ (95%CI)	P	$\beta$ (95%CI)	P
eGFR, (ml/min/1.73m <sup>2</sup> ) categories									
≥90	371(61)	0		0		0		0	
60-90	207(34)	-0.9 (-1.2, -0.6)	<0.001	-0.7 (-1.0, -0.3)	<0.001	-1.5 (-1.8, -1.2)	<0.001	-1.4 (-1.7, -1.0)	<0.001
<60	30(5)	-4.4 (-5.1, -3.8)	<0.001	-4.2 (-5.0, -3.4)	<0.001	-5.3 (-6.0, -4.5)	<0.001	-5.2 (-6.1, -4.4)	<0.001
eGFR per 5-unit decline	608(100)	-0.4 (-0.5, -0.4)	<0.001	-0.4 (-0.5, -0.4)	<0.001	-0.5 (-0.6, -0.5)	<0.001	-0.6 (-0.7, -0.5)	<0.001
UACR(mg/g) categories									
<30	338(56)	0		0		0		0	
30-300	240(39)	-0.1 (-0.4, 0.3)	0.716	0.0 (-0.3, 0.3)	0.971	-0.0 (-0.4, 0.3)	0.858	0.0 (-0.3, 0.3)	0.826
≥300	30(5)	-0.7 (-1.5, 0.0)	0.064	-0.3 (-1.0, 0.4)	0.387	-0.8 (-1.7, 0.0)	0.065	-0.2 (-0.9, 0.6)	0.68
log-UACR	608(100)	-0.2 (-0.6, 0.2)	0.262	-0.0 (-0.4, 0.3)	0.784	-0.3 (-0.6, 0.1)	0.214	-0.0 (-0.4, 0.3)	0.834

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

\*Adjusted for age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either baseline estimated glomerular filtration rate or UACR.

Table 3 Multivariable adjusted\* Linear regression of MMSE scores with UACR and eGFR within subgroups

Subgroups	Comparing UACR (30-300, >300 vs <30mg/g)			P for interaction	Comparing eGFR (60-90, <60 vs ≥90 ml/min/1.73m <sup>2</sup> )			P for interaction
	<30	30-300	>300		≥90	60-90	<60	
	B (95%CI) P				B (95%CI) P			
Gender				0.050				0.123
Male	0	0.3 (-0.1, 0.7) 0.137	-0.5 (-1.5, 0.4) 0.278		0	-1.0 (-1.5, -0.5) <0.001	-4.1 (-5.2, -3.1) <0.001	
Female	0	-0.4 (-0.8, 0.1) 0.104	-0.2 (-1.2, 0.8) 0.703		0	-0.5 (-1.0, -0.0) 0.050	-4.4 (-5.7, -3.1) <0.001	
Age dichotomous				0.588				0.609
Lower	0	-0.0 (-0.5, 0.4) 0.842	-0.7 (-1.7, 0.4) 0.215		0	-0.8 (-1.3, -0.3) 0.002	-5.8 (-7.4, -4.3) <0.001	
Higher	0	0.1 (-0.4, 0.5) 0.717	0.3 (-0.7, 1.3) 0.503		0	-0.8 (-1.2, -0.4) <0.001	-3.9 (-4.6, -3.1) <0.001	
Systolic blood pressure dichotomous				0.657				0.149
Lower	0	-0.1 (-0.5, 0.4) 0.781	-0.2 (-1.3, 0.9) 0.740		0	-0.6 (-1.2, -0.1) 0.021	-2.8 (-4.2, -1.4) <0.001	
Higher	0	0.1 (-0.3, 0.5) 0.652	-0.3 (-1.2, 0.7) 0.562		0	-0.7 (-1.2, -0.2) 0.005	-4.2 (-5.1, -3.3) <0.001	
NIHSS score dichotomous				0.375				0.953
Lower	0	-0.2 (-0.7, 0.3) 0.393	-0.6 (-1.7, 0.5) 0.304		0	-0.6 (-1.1, -0.0) 0.035	-3.7 (-5.4, -2.0) <0.001	
Higher	0	0.1 (-0.3, 0.5) 0.767	-0.0 (-0.9, 0.9) 0.982		0	-0.7 (-1.1, -0.2) 0.006	-4.2 (-5.1, -3.3) <0.001	
Stroke subtypes				0.311				0.122
Large artery	0	0.1 (-0.4, 0.6) 0.661	0.3 (-0.7, 1.3) 0.531		0	-0.8 (-1.4, -0.2) 0.006	-4.3 (-5.3, -3.2) <0.001	
Small vessel occlusion	0	-0.2 (-0.6, 0.2) 0.330	-0.4 (-1.4, 0.6) 0.441		0	-0.5 (-1.0, -0.1) 0.026	-4.0 (-5.3, -2.8) <0.001	
Blood glucose dichotomous				0.849				0.372
Lower	0	-0.3 (-0.9, 0.2) 0.225	-2.5 (-5.2, 0.1) 0.059		0	-1.0 (-1.5, -0.5) <0.001	-4.5 (-5.7, -3.4) <0.001	

Higher	0	0.1 (-0.4, 0.6) 0.768	-0.0 (-1.4, 1.3) 0.951	0	-0.5 (-1.0, 0.0) 0.065	-3.9 (-5.1, -2.8) <0.001
--------	---	-----------------------	------------------------	---	------------------------	--------------------------

---

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

\*Adjusted, if not stratified, age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either estimated glomerular filtration rate or UACR.

Table 4 Multivariable adjusted\* Linear regression of MoCA scores with UACR and eGFR within subgroups

	Comparing UACR (30-300, >300 vs <30mg/g)			P for interaction	Comparing eGFR (60-90, <60 vs ≥90 ml/min/1.73m <sup>2</sup> )			P for interaction
	<30	30-300	>300		≥90	60-90	<60	
Subgroups	B (95%CI) P				B (95%CI) P			
Gender				0.107				0.195
Male	0	0.3 (-0.1, 0.8) 0.149	-0.1 (-1.1, 1.0) 0.910		0	-1.7 (-2.2, -1.1) <0.001	-5.4 (-6.5, -4.3) <0.001	
Female	0	-0.3 (-0.8, 0.2) 0.197	-0.2 (-1.3, 0.8) 0.673		0	-1.1 (-1.7, -0.6) <0.001	-4.8 (-6.2, -3.3) <0.001	
Age dichotomous				0.352				0.341
Lower	0	0.1 (-0.4, 0.6) 0.658	-0.6 (-1.7, 0.6) 0.345		0	-1.3 (-1.9, -0.7) <0.001	-6.1 (-8.0, -4.3) <0.001	
Higher	0	0.1 (-0.4, 0.5) 0.819	0.4 (-0.6, 1.4) 0.411		0	-1.4 (-1.9, -0.9) <0.001	-5.1 (-6.1, -4.1) <0.001	
Systolic blood pressure dichotomous				0.595				0.402
Lower	0	0.0 (-0.5, 0.5) 0.922	0.1 (-1.0, 1.3) 0.825		0	-1.2 (-1.8, -0.7) <0.001	-4.2 (-5.6, -2.7) <0.001	
Higher	0	0.0 (-0.4, 0.4) 0.969	-0.3 (-1.3, 0.7) 0.533		0	-1.4 (-1.9, -0.9) <0.001	-5.7 (-6.8, -4.6) <0.001	
NIHSS score dichotomous				0.422				0.835
Lower	0	-0.3 (-0.8, 0.3) 0.318	-0.1 (-1.2, 1.1) 0.932		0	-1.3 (-1.9, -0.7) <0.001	-5.1 (-7.0, -3.3) <0.001	
Higher	0	-0.1 (-1.2, 1.1) 0.932	-0.1 (-1.0, 0.9) 0.879		0	-1.4 (-1.9, -0.9) <0.001	-5.3 (-6.3, -4.4) <0.001	
Stroke subtypes				0.391				0.576
Large artery	0	0.3 (-0.2, 0.7) 0.277	0.2 (-0.8, 1.3) 0.653		0	-1.4 (-2.0, -0.8) <0.001	-4.9 (-6.0, -3.8) <0.001	
Small vessel occlusion	0	-0.2 (-0.7, 0.2) 0.310	0.1 (-1.0, 1.2) 0.825		0	-1.3 (-1.8, -0.8) <0.001	-5.7 (-7.1, -4.2) <0.001	
Blood glucose dichotomous				0.409				0.585
Lower	0	0.0 (-0.4, 0.5) 0.960	-0.5 (-1.5, 0.5) 0.303		0	-1.7 (-2.3, -1.1) <0.001	-5.3 (-6.6, -4.0) <0.001	
Higher	0	-0.0 (-0.5, 0.4) 0.838	-0.1 (-1.1, 1.0) 0.918		0	-1.1 (-1.7, -0.6) <0.001	-5.1 (-6.3, -3.9) <0.001	

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

\*Adjusted, if not stratified, age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either estimated glomerular filtration rate or UACR.

Table 5 Association of joint UACR and eGFR stratum with cognitive performance ( $\beta$  95% CI)

eGFR, (ml/min/1.73m <sup>2</sup> )		MMSE		MoCA	
		UACR(mg/g) categories		UACR(mg/g) categories	
		<30	≥30	<30	≥30
≥90	Crude	0.00	0.0 (-0.4, 0.4)	0.00	0.2 (-0.3, 0.6)
	Adjusted*	0.00	-0.0 (-0.4, 0.4)	0.00	0.1 (-0.3, 0.6)
<90	Crude	-1.2 (-1.7, -0.8)	-1.5 (-2.0, -1.0)	-1.7 (-2.2, -1.3)	-2.1 (-2.6, -1.6)
	Adjusted*	-0.8 (-1.3, -0.4)	-1.0 (-1.5, -0.5)	-1.4 (-1.9, -0.9)	-1.7 (-2.3, -1.2)

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR, urine albumin-creatinine ratio.

\* adjusted for age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure.